Related references
Note: Only part of the references are listed.
Article
Pediatrics
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Eric A. F. Simoes et al.
Summary: This study evaluated the efficacy of nirsevimab using a weight-banded dosing regimen in infants born between 29 weeks gestational age and full term. The results showed that a single dose of nirsevimab protected healthy infants born at term or preterm from RSV lower respiratory tract infection, reducing the incidence of hospital admissions and severe cases associated with RSV. Therefore, nirsevimab has the potential to alleviate the burden of infant RSV disease.
LANCET CHILD & ADOLESCENT HEALTH (2023)
Article
Medicine, General & Internal
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Article
Infectious Diseases
Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020
Stefano Tempia et al.
Eurosurveillance (2021)
Share Paper
